Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Pyxis Oncology is a clinical-stage biotech focused on developing antibody-drug conjugates (ADCs) targeting tumor extracellular matrix components, particularly EDB+FN, to treat solid tumors like head and neck squamous cell carcinoma. Its lead candidate, micvotabart pelidotin, aims to disrupt tumor support structures, induce tumor cell death, and stimulate immune responses. The company advances innovative ADC platforms and collaborates to address unmet oncology needs.
This description was generated via AI from an annual report. Updated about 1 year ago.